Nurturing the stem cell business: Lessons from the recombinant drugs markets?

International Journal of Biotechnology

Volumn 8, Issue 3-4, 2006, Pages 187-205

  Junold, Robert ^a   Wink, Rüdiger ^a,b,c  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b LEIPZIG UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c RUFIS   (Germany)

Author keywords

Geographical proximity; Knowledge asymmetries; Recombinant drugs; Science driven sectors; Stem cell research

Indexed keywords

KNOWLEDGE ACQUISITION; MARKETING; SALES; TISSUE;

GEOGRAPHICAL PROXIMITY; KNOWLEDGE ASYMMETRIES; RECOMBINANT DRUGS; SCIENCE-DRIVEN SECTORS; STEM CELL RESEARCH;

DRUG PRODUCTS;

BUSINESS; DRUG; MARKETING; POLICY IMPLEMENTATION; STEM;

BIOTECHNOLOGY; COMMERCIAL PHENOMENA; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; FUNDING; GEOGRAPHIC DISTRIBUTION; HUMAN; METHODOLOGY; ORGANIZATION; PHARMACEUTICS; POLICY; POLITICAL SYSTEM; REVIEW; STEM CELL;

EID: 33646228834     PISSN: 09636048     EISSN: None     Source Type: Journal    
DOI: 10.1504/ijbt.2006.009291     Document Type: Review

References (50)

1. Agarwal, R. and Audretsch, D.B. (2001) 'Does entry size matter? The impact of the life cycle and technology on firm survival', Journal of Industrial Economics, Vol. 49, pp.21-44.
2. Aharonson, B.S., Baum, J.A.C. and Feldman, M.P. (2004) 'Industrial clustering and the returns to inventive activity: Canadian biotechnology firms, 1991-2000', DRUID Working Papers, Copenhagen, Nos. 04-03.
3. Aksoy, S. (2005) 'Making regulations and drawing up legislation in Islamic countries under conditions of uncertainty, with special reference to embryonic stem cell research', Journal of Medical Ethics, Vol. 31, pp.399-403.
4. Antinori, S. and Zavos, P. (2001) 'If the royal society is having a debate on cloning then let's have a debate and not a monologue', Sunday Herald, Glasgow.
5. Bathelt, H., Malmberg, A. and Maskell, P. (2002) 'Clusters and knowledge: local buzz, global pipelines, and the process of knowledge creation', DRUID Working Paper 2002-12, Copenhagen.
6. Beier, H.M. (2005) 'Am Beginn des Weges zu regenerativen Therapien: Patientenspezifische embryonale Stammzellen nach somalischem Zellkerntransfer', Journal der Reproduktionsmedizin und Endokrinologie, Vol. 2, pp.76-77.
7. Bernier, L. and Gregoire, D. (2004) 'Reproductive and therapeutic cloning, germline therapy, and purchase of gametes and embryos: comments on Canadian legislation governing reproduction technologies', Journal of Medical Ethics, Vol. 30, pp.527-532.
8. Blum, U. and Müller, S. (2004) 'The role of intellectual property rights regimes for R&D-cooperation between industry and academia', in R. Wink (Ed.) Academia-Business Linkages. Policy Strategies and Lessons Learnt, Houndmills, pp.97-109.
9. Bonnicksen, A.L. (2002) Crafting a Cloning Policy: From Dolly to Stem Cells, Washington, DC.
10. Brownsword, R. (2004) 'Regulating human genetics: new dilemmas for a new millennium', Medical Law Review, Vol. 12, pp.14-39.
11. Brusoni, S. and Prencipe, A. (2001) 'Managing knowledge in loosely coupled networks: exploring the links between product and knowledge', Journal of Management Studies, Vol. 38, pp.1019-1035.
12. Canadian Institute of Health Research (2001) Human Stem Cell Research: Opportunities for Health and Ethical Perspectives, Ottawa.
13. Caulfield, T., Knowles, L. and Meslin, E.M. (2004) 'Law and policy in the era of reproductive genetics', Journal of Medical Ethics, Vol. 30, pp.414-417.
14. Chalmers, D. and Nicol, D. (2003) 'Embryonic stem cell research: can the law balance ethical, scientific and economic values? (Part I and II)', Law and Human Genome Review, Vol. 18, pp.43-53, 91-108.
15. Chalmers, D. and Nicol, D. (2004) 'Commercialisation of biotechnology: public trust and research', International Journal of Biotechnology, Vol. 6, pp.116-133.
16. Champenois, C., Engel, D. and Heneric, O. (2004) The Birth of German Biotechnology Industry: Did Venture Capital Run the Show?, Mannheim.
17. Commission of the European Communities (2003) Report on Human Embryonic Stem Cell Research, Brussels.
18. Cooke, P. (2005) 'Rational drug design, the knowledge value chain, and bioscience megacentres', Cambridge Journal of Economics, Vol. 29, pp.325-341.
19. Deeds, D-L. and Hill, C.W-L. (1999) 'An examination of opportunistic action within research alliances: evidence from the biotechnology industry', Journal of Business Venturing, Vol. 14, pp.141-163.
20. Devolder, K. (2005) 'Creating and sacrificing embryos for stem cells', Journal of Medical Ethics, Vol. 31, pp.366-370.
21. DiMasi, J.A., Hansen, R.W. and Grabowski, H.G. (2003) 'The price of innovation: new estimations of drug development costs', Journal of Health Economics, Vol. 22, pp.151-185.
22. Dohse, D. (2000) 'Technology policy and the regions - the case of the bioRegio contest', Research Policy, Vol. 29, pp.1111-1133.
23. Du, J., et al. (2004) 'Stem cell mission to China, Singapore and South Korea', Report of a DTI Global Watch Mission, London.
24. Enerbäck, L. and Lindsten, J. (2002) Survey of stem cell research in Sweden, study commissioned by the Swedish Council for Medicine, Stockholm.
25. Fuchs-Kittowski, K., Rosenthal, A. and Rosenthal, H.A. (2005) 'Ambivalenz der Auswirkungen Humangentechnischer Forschung auf Gesellschaft und Forschung', Jahrbuch der Forschung 2005, Berlin.
26. Gratton, B. (2002) Survey on the National Regulations in the European Union Regarding Research on Human Embryos, Brussels.
27. Halliday, S. (2004) 'A comparative approach to the regulation of human embryonic stem cell research in Europe', Medical Law Review, Vol. 12, pp.40-69.
28. Henderson, R., Orsenigo, L. and Pisano, G. (1999) 'The pharmaceutical industry and the revolution in molecular biology: interactions among scientific, institutional and organisational change', in D. Mowery and R. Nelson (Eds.) Sources of Industrial Leadership, Cambridge, pp.43-64.
29. Howells, J. (2002) 'A European innovation system in pharmaceuticals?', International Journal of Biotechnology, Vol. 4, pp.96-114.
30. Koh, C.J. and Atala, A. (2004) 'Therapeutic cloning and tissue engineering', Current Topics of Development Biology, Vol. 60, pp.1-15.
31. Lysaght, M.J. and Hazlehurst, A.L. (2003) 'Private sector development of stem cell technology and therapeutical cloning', Tissue Engineering, Vol. 9, pp.555-561.
32. Lysaght, M.J. and Hazlehurst, A.L. (2004) 'Tissue engineering: the end of the beginning', Tissue Engineering, Vol. 10, pp.309-320.
33. Malinowski, M.J. (2000) 'Biotechnology in the USA: responsive regulation in the life science industry', International Journal of Biotechnology, Vol. 2, pp.16-26.
34. Maskell, P. (2001) 'Towards a knowledge-based theory of the geographic cluster', Industrial and Corporate Change, Vol. 10, pp.921-943.
35. Nesta, L. and Mangematin, V. (2002) 'Industry life cycle, knowledge generation and technological networks', in F. Gault and J. de la Mothe (Eds.) Alliances, Networks, and Partnerships in the Innovation Process, Ottawa, pp.117-140.
36. Okie, M.D. (2005) 'Stem-cell research - signposts and roadblocks', New England Journal of Medicine, Vol. 353, No. 1, pp.1-5.
37. Orsenigo, L., Pammolli, F. and Riccaboni, M. (2001) 'Technological change and network dynamics: lessons from the pharmaceutical industry', Research Policy, Vol. 30, pp.485-508.
38. Owen-Smith, J. and Powell, W.W. (2003) 'Knowledge networks as channels and conduits: the effects of spill-overs in the Boston biotechnology community', Organization Science.
39. Pangarkar, N. and Hutmacher, D.W. (2003) 'Invention and business performance in the tissue-engineering industry', Tissue Engineering, Vol. 9, pp.1313-1322.
40. Pompe, S., Bader, M. and Tannert, C. (2005) 'Stem-cell research: the state of the art', European Molecular Biology Organization Reports, Vol. 6, pp.297-300.
41. Porter, M.E. (2000) 'Locations, clusters, and company strategy', in G.L. Clark, M.P. Feldman and M.S. Gertler (Eds.) The Oxford Handbook of Economic Geography, Oxford.
42. Powell, W.W., Koput, K.W. and Smith-Doerr, L. (1996) 'Interorganizational collaboration and the locus of innovation: networks of learning in biotechnology', Administrative Science Quarterly, Vol. 41, pp.116-145.
43. President's Council on Bioethics (2004) Monitoring Stem Cell Research, Washington.
44. Regnier, M-H. and Knoppers, B-M. (2003) 'International initiatives on stem cell research', Health Law Review, Vol. 11, pp.67-71.
45. Schutte, E. (2002) 'Regulatory barriers to tissue-engineered products', Medical Device Technologies, Vol. 13, pp.27-29.
46. Towns, C.R. and Jones, D.G. (2004) 'Stem cells, embryos, and the environment: a context for both science and ethics', Journal of Medical Ethics, Vol. 30, pp.410-413.
47. Valentin, F. and Jensen, R.L. (2002) 'Reaping the fruits of science', Economic Systems Research, Vol. 14, pp.363-388.
48. Wiedemann, P.M., et al. (2004) 'The future of stem-cell research in Germany - a Delphi study', European Molecular Biology Organization Reports, Vol. 5, pp.927-931.
49. Wink, R. (2004) 'Commercialisation of bio-pharmaceutical therapies and risk management: the impact on the sustainability of markets for recombinant drugs', Journal of Biotechnology, Vol. 7, pp.186-201.
50. Winterhager, M. and Camargo, A. (2005) Institutional Cooperation in Stem Cell Research and Co-publications, Bielefeld.